AxoGen, Inc. (AXGN)
Automate Your Wheel Strategy on AXGN
With Tiblio's Option Bot, you can configure your own wheel strategy including AXGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AXGN
- Rev/Share 4.3032
- Book/Share 2.3309
- PB 4.6764
- Debt/Equity 0.1967
- CurrentRatio 4.2801
- ROIC -0.0027
- MktCap 496429600.0
- FreeCF/Share 0.0324
- PFCF 339.323
- PE -68.7874
- Debt/Assets 0.1057
- DivYield 0
- ROE -0.0709
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | AXGN | Lake Street | -- | Buy | -- | $30 | March 17, 2025 |
News
AxoGen (AXGN) Loses 25.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Negative
The heavy selling pressure might have exhausted for AxoGen (AXGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read More
AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative
AxoGen (AXGN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to loss of $0.06 per share a year ago.
Read More
Axogen, Inc. Reports 2025 First Quarter Financial Results
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2025.
Read More
Axogen, Inc. (AXGN) Q4 2024 Earnings Call Transcript
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Neutral
Axogen, Inc. (NASDAQ:AXGN ) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ET Company Participants Michael Dale - Chairman and Chief Executive Officer Nir Naor - Chief Financial Officer Jens Kemp - Chief Marketing Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Caitlin Cronin - Canaccord Genuity Mike Kratky - Leerink Partners Jayson Bedford - Raymond James Ross Osborn - Cantor Fitzgerald Dave Turkaly - Citizens JMP Operator Good morning everyone. Joining me on today's call is Michael Dale, Axogen's Chief Executive Officer and Director; and Nir Naor, Chief Financial Officer; and Jens …
Read More
Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
ALACHUA, Fla. and TAMPA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2024 fourth quarter and full year financial results on Tuesday, February 25, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release.
Read More
About AxoGen, Inc. (AXGN)
- IPO Date 1986-12-17
- Website https://www.axogeninc.com
- Industry Medical - Devices
- CEO Mr. Michael D. Dale
- Employees 451